Metformin inhibits gluconeogenesis, which contributes to its efficacy in reducing hepatic glucose output.

“this also explains why we rarely see clinically hypoglycemia on patients treated with metformin because there's these alternative gluconeogenic substrates that can come in alanine can keep coming out so you never see rarely unless they have another agent on top of metformin like insulin or su you rarely see it if ever”